Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma

ISBN-13: 9784431402800 / Angielski / Twarda / 2004 / 295 str.

Masao Omata; Kiwamu Okita; M. Omata

Opis

The first single-topic annual conference on hepatology in Japan was held in November 2002 to discuss therapies for viral hepatitis and the prevention of hepatocellular carcinoma (HCC). Bringing together researchers and clinicians from North America, Europe, Japan, and other parts of Asia, the conference included symposia on the hepatitis C replicon system, new antivirals that lower or prevent the incidence of HCC, and transplantation in cases of hepatitis B and C, as well as new treatment modalities for viral hepatitis and preventative measures for HCC. With the rising number of HCC cases worldwide, this collection of papers presented at the conference provides a valuable, up-to-date resource and reference for all professionals involved in the treatment and prevention of viral hepatitis and hepatocellular carcinoma.

Spis treści

1 Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma.- 1.1 Opening Lecture: What is Accomplished and What is Needed.- 2 Lamivudine Therapy for Hepatitis B.- 2.1 New Anti-Virals Against Wild-Type and Lamivudine-Resistant Hepatitis B Virus.- 2.2 Lamivudine Therapy of Hepatitis B in Japan.- 2.3 Early Detection of Lamivudine Resistant Mutant in Chronic Hepatitis B Patients Using a Novel Sensitive Method.- 3 New Anti-Virals: HBV.- 3.1 New Antiviral Treatment for Chronic Hepatitis B.- 3.2 New Antiviral Therapy: Adefovir Dipivoxil for HBV.- 3.3 Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection.- 4 Therapy for Hepatitis B and Prevention of HCC.- 4.1 Therapy of Hepatitis B and Prevention of Hepatocellular Carcinoma.- 4.2 Differences of Clinical Characteristics Among Japanese Patients with Hepatitis B Virus Genotypes B and C.- 5 HCV Replicon System.- 5.1 Establishment of a New Hepatitis C Virus-l b Replicon.- 5.2 Hepatitis C Virus Replication in Cell Culture.- 5.3 Characterization of the Interferon Alpha Response Against HCV in Hepatoma Cells.- 6 New Anti-Virals: HCV.- 6.1 Hepatitis C: Development of a Ribavirin Liver-Targeting Prodrug.- 6.2 HCV Replicon Inhibitors: Mode of Action and Resistance Mapping.- 7 Interferon Therapy for Hepatitis C.- 7.1 Interferon Treatment Not Only Reduces the Risk of Hepatocellular Carcinoma But Also Improves Mortality in Patients with Chronic Hepatitis C Showing Biochemical Response, Especially in Patients with Advanced Liver Fibrosis.- 7.2 Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon.- 7.3 IFN Receptor and IFN Signals.- 8 Therapy for Hepatitis C and Prevention of HCC.- 8.1 Management and Treatment of Hepatitis C.- 8.2 Hepatitis C Virus and Hepatocellular Carcinoma.- 8.3 Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome.- 8.4 Roles of Antiviral Therapy in Chronic Hepatitis C Patients Should be Different According to the Stages of Liver Disease Progression.- 8.5 Significance of Sustained Inflammation in the Development of HCC from HCV-Associated Cirrhotic Patients and the Prevention of HCC by Anti-Inflammatory Agents.- 9 Chemoprevention and Therapy for HCC.- 9.1 Chemoprevention of Hepatocellular Carcinoma with Retinoid.- 9.2 Vitamin K2Administration Improves the Prognoses of Patients with Hepatocellular Carcinoma Presenting High Levels of Serum Des-?-Carboxy Prothrombin.- 9.3 Combination Chemotherapy for Advanced Hepatocellular Carcinoma.- 9.4 Combined Intra-Arterial 5-Fluorouracil and Subcutaneous Interferon-Alpha Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombi in the Major Portal Branches.- 10 Transplantation for HBV and HCV.- 10.1 Liver Transplantation for Hepatitis B Virus-Related Liver Disease.- 10.2 Living Donor Liver Transplantation for Hepatitis B and C Cirrhosis.- 10.3 Living Donor Liver Transplantation for HBV-/HCV-Related Diseases.

O autorze

Kiwamu Okita

Professor, Department of Gastroenterology and Hepatology, Yamaguchi University School of Medicine

Blurb

The liver has an important role in nutritional homeostasis, and it is well known that liver diseases can lead to abnormalities in the nutrient metabolism and to subsequent malnutrition. Because malnutrition is particularly prevalent in patients with liver cirrhosis, proper nutritional assessment and support for cirrhotic patients is essential. This collection of research and clinical findings on nonalcoholic steatohepatitis (NASH) and nutritional therapy contains significant new findings in several fields. As NASH frequently causes liver cirrhosis, the nutritional aspects of its treatment are discussed. Other areas covered include nonalcoholic fatty liver, the role of leptin in the pathogenesis of NASH, restricted diets and exercise therapy, mammalian targets of the peptide rapamycin, and genetic factors influencing the development of NASH. This book is intended to be of particular relevance to researchers and those practicing in the field.